Within the last two decades, major advances have been made in the development of effective treatments for erectile dysfunction. Oral therapy is now established as the mainstay of treatment and new treatments continue to emerge following the launch of sildenafil in 1998. We review here modern treatment strategies for erectile dysfunction.
Lue TF, Mueller SC, Jow YR, Hwang TIFunctional evaluation of penile arteries with duplex ultrasound in vasodilator-induced erection. Urol Clin North Am1989;16:799-807.
4.
Melman A., Gingell JCThe epidemiology and pathophysiology of erectile dysfunction. J Urol1999;161:5-11.
5.
Saenz de Tejada I., Goldstein I., Azadzoi K., Krane RJ, Cohen RAImpaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med1989;320:1025-30.
6.
Feldman HA, Goldstein I., Hatzichristou DG, Krane RJ, McKinlay JBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol1994;151:54-61.
7.
Derby CA, Mohr BA, Goldstein I., Feldman HA, Johannes CB, McKinlay JBModifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?Urology2000;56:302-06.
8.
Lizza EF, Rosen RCDefinition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research . Int J Impot Res1999;11:141-3.
9.
Schwarzer U. , Sommer F., Klotz T., Cremer C., Engelmann U.Cycling and penile oxygen pressure: the type of saddle matters. Eur Urol2002;41: 139-43.
10.
Sommer F., Konig D., Graft C., Schwarzer U., Bertram C., Klotz T., Engelmann U.Impotence and genital numbness in cyclists. Int J Sports Med2001;22:410-13.
11.
Curry A.Holey bike seats! You won't believe what cycling could do to you. US News World Rep2000;129:53.
12.
Masters WH, Johnson V.Human sexual inadequacy. Boston, Little, Brown & Co., 1970.
13.
Lue TF, Broderick G.Evaluation and nonsurgical management of erectile dysfunction and priapism . In Walsh PC, Retik AB, Vaughan ED , Wein AJ eds. Campbell's Urology. 7th edn. Vol. 2. Chapter 39. Philadelphia: Saunders .1998:1181-214.
14.
Morales A., Surridge DH, Marshall PG, Fenemore J.Nonhormonal pharmacological treatment of organic impotence. J Urol1982;128:45-7.
15.
Reid K., Surridge DH, Morales A. et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet1987;2:421-3.
16.
Goldstein I. , Lue TF, Padma-Nathan H., Rosen RC, Steers WD, Wicker PAOral sildenafil in the treatment of erectile dysfunction. 1998. J Urol2002;167:1197-203.
17.
Goldstein I. , Lue TF, Padma-Nathan H., Rosen RC, Steers WD, Wicker PAOral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med1998;338:1397-404.
18.
Klotz T., Sachse R., Heidrich A. et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol2001;19:32-9.
19.
Saenz de Tejada I., Angulo J., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE-5 inhibitor vardenafil . Int J Impot Res2001 ;13:282-90.
20.
Porst H., Rosen R., Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res2001;13:192-9.
21.
Eardley I., Cartledge J.Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract2002;56:300-04.
22.
Porst H.IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res2002;14(suppl 1):S57-S64.
23.
Heaton JP, Dean J., Sleep DJSequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res2002 ;14:61-4.
24.
Mirone VG, Stief CGEfficacy of apomorphine SL in erectile dysfunction. BJU Int2001;88(suppl 3):25-9.
25.
Dula E., Bukofzer S., Perdok R., George M.Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol2001;39:558-63.
26.
Bukofzer S. , Livesey N.Safety and tolerability of apomorphine SL (Uprima). Int J Impot Res2001;139(suppl 3):S40-S44.
27.
Morales A., Johnston B., Heaton JW, Clark A.Oral androgens in the treatment of hypogonadal impotent men. J Urol1994;152:1115-18.
28.
Derouet H., Caspari D., Rohde V., Rommel G., Ziegler M.Treatment of erectile dysfunction with external vacuum devices. Andrologia1999;31 (suppl 1):89-94.
29.
Kiely EA, Ignotus P., Williams G.Penile function following intracavernosal injection of vasoactive agents or saline. Br J Urol1987;59:473-6.
30.
Gasser TC, Roach RM, Larsen EH, Madsen PO, Bruskewitz RCIntracavernous self-injection with phentolamine and papaverine for the treatment of impotence. J Urol1987;137:678-80.
31.
Virag R.Intracavernous injection of papaverine for erectile failure. 1982. J Urol2002;167:1196.
32.
Tsai YS, Lin JS, Lin YMSafety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol2000;38:177-83.
33.
Brock G., Tu LM, Linet OIReturn of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology2001; 57:536-41.
34.
Wolfson B., Pickett S., Scott NE, DeKernion JB, Rajfer J.Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology1993;42:73-5.
